FDA approved lutetium Lu 177 dotatate for the treatment of somatostatin receptor-positive GEP-NETs

/0 Comments/in /by

 

You might also like
TKR inhibitor larotrectinib (Vitrakvi®) FDA approved for cancers with NTRK gene fusion
Atezolizumab FDA approved for extensive-stage small cell lung cancer (SCLC)
Venetoclax plus azacitidine, decitabine, or low-dose cytarabine FDA approved in elderly AML patients
PD-1 mAB cemiplimab FDA approved for locally advanced and metastatic cutaneous squamous cell carcinoma (CSCC)
Ribociclib FDA label updated to include pre- and perimenopausal women©United States Food and Drug Agency Obinutuzumab plus chemotherapy FDA approved for follicular lymphoma
More Information.  June 19, 2018">More Information.  June 19, 2018" alt="FDA  has limited the use of Tecentriq and Keytruda for patients with locally advanced or metastatic urothelial cancer who are not eligible for cisplatin-containing therapy.  More Information.  June 19, 2018" height="180" width="180" srcset="https://medi-paper.com/wp-content/uploads/2018/07/FDA-has-limited-the-use-of-Tecentriq-and-Keytruda-for-patients-with-locally-advanced-or-metastatic-urothelial-cancer-who-are-not-eligible-for-cisplatin-containing-therapy.-More-Information-.-June-19-2018-e1537925445648-180x180.jpg 180w, https://medi-paper.com/wp-content/uploads/2018/07/FDA-has-limited-the-use-of-Tecentriq-and-Keytruda-for-patients-with-locally-advanced-or-metastatic-urothelial-cancer-who-are-not-eligible-for-cisplatin-containing-therapy.-More-Information-.-June-19-2018-e1537925445648-80x80.jpg 80w, https://medi-paper.com/wp-content/uploads/2018/07/FDA-has-limited-the-use-of-Tecentriq-and-Keytruda-for-patients-with-locally-advanced-or-metastatic-urothelial-cancer-who-are-not-eligible-for-cisplatin-containing-therapy.-More-Information-.-June-19-2018-e1537925445648-36x36.jpg 36w, https://medi-paper.com/wp-content/uploads/2018/07/FDA-has-limited-the-use-of-Tecentriq-and-Keytruda-for-patients-with-locally-advanced-or-metastatic-urothelial-cancer-who-are-not-eligible-for-cisplatin-containing-therapy.-More-Information-.-June-19-2018-e1537925445648-120x120.jpg 120w, https://medi-paper.com/wp-content/uploads/2018/07/FDA-has-limited-the-use-of-Tecentriq-and-Keytruda-for-patients-with-locally-advanced-or-metastatic-urothelial-cancer-who-are-not-eligible-for-cisplatin-containing-therapy.-More-Information-.-June-19-2018-e1537925445648-450x450.jpg 450w" sizes="(max-width: 180px) 100vw, 180px"> FDA limits use of atezolizumab and pembrolizumab in urothelial carcinoma
Ribociclib FDA label updated to include pre- and perimenopausal women©United States Food and Drug Agency FDA safety alert: use of immunotherapy in metastatic urothelial cancer with low PD-L1 expression
Ribociclib FDA label updated to include pre- and perimenopausal women©United States Food and Drug Agency Abemaciclib in combination with fulvestrant FDA approved for HR+, HER2- advanced or metastatic breast cancer progressing following endocrine therapy
0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply